Teiko.bio

Preclinical Discovery

Enter IND and Phase 1 studies with validated targets and mechanistic insights predictive of therapeutic response.
search icon

Target Identification

Profile over 1T marker combinations to identify novel targets across the innate and adaptive immune system.

branching icon

Mechanism of Action

Understand the complex network of immune cell interactions associated with your target.

group of hexagons icon

Target Validation

Select an approach that maximizes therapeutic response to facilitate entry into IND-study.

Mechanism of Action

Before Teiko.bio

Before Teiko.bio

The assumption is CD8 T cells need to be targeted directly. However, this leads to therapy failure.

With Teiko.bio

With Teiko.bio

Immune profiling reveals the actual issue is upstream, with dendritic cells not being activated.

After Teiko.bio

After Teiko.bio

Upstream anti-CD40 therapy activates dendritic cells to create therapy success.

Target Validation

  • Identify approaches that maximize therapeutic effect
  • Which combination strategies to pursue
  • Validate a therapeutic approach and target to enter for IND-stage study